Development of a VRC01-class germline targeting immunogen derived from anti-idiotypic antibodies.

B cell receptor HIV-1 anti-idiotypic antibodies antibody heavy chain antibody light chain broadly neutralizing antibodies vaccines

Journal

Cell reports
ISSN: 2211-1247
Titre abrégé: Cell Rep
Pays: United States
ID NLM: 101573691

Informations de publication

Date de publication:
04 05 2021
Historique:
received: 30 10 2020
revised: 08 03 2021
accepted: 13 04 2021
entrez: 5 5 2021
pubmed: 6 5 2021
medline: 11 2 2022
Statut: ppublish

Résumé

An effective HIV-1 vaccine will likely need to elicit broadly neutralizing antibodies (bNAbs). Broad and potent VRC01-class bNAbs have been isolated from multiple infected individuals, suggesting that they could be reproducibly elicited by vaccination. Several HIV-1 envelope-derived germline-targeting immunogens have been designed to engage naive VRC01-class precursor B cells. However, they also present off-target epitopes that could hinder development of VRC01-class bNAbs. We characterize a panel of anti-idiotypic monoclonal antibodies (ai-mAbs) raised against inferred-germline (iGL) VRC01-class antibodies. By leveraging binding, structural, and B cell sorting data, we engineered a bispecific molecule derived from two ai-mAbs; one specific for VRC01-class heavy chains and one specific for VRC01-class light chains. The bispecific molecule preferentially activates iGL-VRC01 B cells in vitro and induces specific antibody responses in a murine adoptive transfer model with a diverse polyclonal B cell repertoire. This molecule represents an alternative non-envelope-derived germline-targeting immunogen that can selectively activate VRC01-class precursors in vivo.

Identifiants

pubmed: 33951425
pii: S2211-1247(21)00417-4
doi: 10.1016/j.celrep.2021.109084
pmc: PMC8127986
mid: NIHMS1700552
pii:
doi:

Substances chimiques

AIDS Vaccines 0
HIV Antibodies 0

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, U.S. Gov't, Non-P.H.S.

Langues

eng

Sous-ensembles de citation

IM

Pagination

109084

Subventions

Organisme : NIAID NIH HHS
ID : R01 AI081625
Pays : United States
Organisme : NIAID NIH HHS
ID : R21 AI127249
Pays : United States
Organisme : NIGMS NIH HHS
ID : P30 GM133894
Pays : United States
Organisme : NIH HHS
ID : S10 OD021832
Pays : United States
Organisme : NIAID NIH HHS
ID : P01 AI138212
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI122912
Pays : United States

Commentaires et corrections

Type : ErratumIn

Informations de copyright

Published by Elsevier Inc.

Déclaration de conflit d'intérêts

Declaration of interests The authors declare no competing interests.

Références

Nat Med. 2000 Feb;6(2):200-6
pubmed: 10655110
Immunity. 2014 May 15;40(5):657-68
pubmed: 24768347
J Immunol Methods. 2009 Oct 31;350(1-2):183-93
pubmed: 19716372
Acta Crystallogr D Biol Crystallogr. 2010 Feb;66(Pt 2):213-21
pubmed: 20124702
Cell. 2014 Feb 13;156(4):633-48
pubmed: 24529371
J Virol. 1999 May;73(5):4009-18
pubmed: 10196297
Curr Opin Immunol. 2018 Aug;53:209-216
pubmed: 30190230
Science. 2020 Aug 28;369(6507):1119-1123
pubmed: 32661058
Cell. 2016 Sep 8;166(6):1471-1484.e18
pubmed: 27610571
Science. 2016 Mar 25;351(6280):1458-63
pubmed: 27013733
J Virol. 2013 Aug;87(15):8535-44
pubmed: 23720722
Proc Natl Acad Sci U S A. 2013 Apr 9;110(15):6049-54
pubmed: 23524883
PLoS Pathog. 2013 Jan;9(1):e1003106
pubmed: 23300456
Science. 2013 May 10;340(6133):711-6
pubmed: 23539181
J Exp Med. 2017 Sep 4;214(9):2573-2590
pubmed: 28847869
Nature. 2011 Nov 30;481(7379):81-4
pubmed: 22139420
Cell. 2015 Jun 18;161(7):1505-15
pubmed: 26091035
Science. 2016 Sep 30;353(6307):1557-1560
pubmed: 27608668
Nature. 2014 Nov 6;515(7525):138-42
pubmed: 25186731
Immunity. 2020 Sep 15;53(3):548-563.e8
pubmed: 32857950
J Virol. 2012 Apr;86(8):4688-92
pubmed: 22301150
Cell. 2016 Sep 8;166(6):1459-1470.e11
pubmed: 27610570
Nature. 2012 Nov 15;491(7424):406-12
pubmed: 23151583
Nature. 2009 Apr 2;458(7238):636-40
pubmed: 19287373
Nat Commun. 2020 Oct 27;11(1):5413
pubmed: 33110068
Cell. 2013 Mar 28;153(1):126-38
pubmed: 23540694
Sci Transl Med. 2018 Jul 4;10(448):
pubmed: 29973404
Science. 2011 Sep 16;333(6049):1593-602
pubmed: 21835983
Nat Struct Mol Biol. 2016 Oct;23(10):906-915
pubmed: 27617431
Methods Enzymol. 1997;276:307-26
pubmed: 27754618
Cell. 2015 Jun 4;161(6):1280-92
pubmed: 26004070
AIDS Res Hum Retroviruses. 1998 Aug 10;14(12):1035-43
pubmed: 9718118
Proc Natl Acad Sci U S A. 2012 Sep 25;109(39):15859-64
pubmed: 23019371
Nucleic Acids Res. 2008 Jul 1;36(Web Server issue):W503-8
pubmed: 18503082
Proc Natl Acad Sci U S A. 2012 Jul 24;109(30):E2083-90
pubmed: 22745174
Proc Natl Acad Sci U S A. 2012 Mar 20;109(12):E690-7
pubmed: 22366317
Annu Rev Immunol. 2016 May 20;34:635-59
pubmed: 27168247
Science. 2009 Oct 9;326(5950):285-9
pubmed: 19729618
Cell. 2018 Jun 14;173(7):1783-1795.e14
pubmed: 29731169
J Mol Biol. 2018 Feb 2;430(3):337-347
pubmed: 29273204
Elife. 2018 Nov 07;7:
pubmed: 30403372
J Virol. 2001 Sep;75(17):8340-7
pubmed: 11483779
Proc Natl Acad Sci U S A. 2016 May 10;113(19):E2636-45
pubmed: 27114511
Proc Natl Acad Sci U S A. 2018 May 1;115(18):4743-4748
pubmed: 29666227
Immunity. 2016 Nov 15;45(5):1108-1121
pubmed: 27851912
J Immunol Methods. 2008 Jan 1;329(1-2):112-24
pubmed: 17996249
Science. 2011 Aug 12;333(6044):850-6
pubmed: 21798894
Immunity. 2020 Oct 13;53(4):840-851.e6
pubmed: 33053332
J Virol. 2015 Jun;89(11):5895-903
pubmed: 25787288
Acta Crystallogr D Biol Crystallogr. 2010 Apr;66(Pt 4):486-501
pubmed: 20383002
Methods Mol Biol. 2009;504:351-83
pubmed: 19159106
Science. 2011 Sep 16;333(6049):1633-7
pubmed: 21764753
Nat Immunol. 2019 Mar;20(3):362-372
pubmed: 30742080
Nature. 2007 Sep 6;449(7158):101-4
pubmed: 17805298
Proc Natl Acad Sci U S A. 2020 Sep 15;117(37):22920-22931
pubmed: 32873644
Immunity. 2018 Apr 17;48(4):799-811.e9
pubmed: 29669253
Acta Crystallogr D Biol Crystallogr. 2004 Dec;60(Pt 12 Pt 1):2126-32
pubmed: 15572765
Acta Crystallogr D Biol Crystallogr. 2012 Apr;68(Pt 4):352-67
pubmed: 22505256
Proc Natl Acad Sci U S A. 2012 Nov 13;109(46):18921-5
pubmed: 23100539
J Exp Med. 2019 Oct 7;216(10):2331-2347
pubmed: 31345930
Immunity. 2018 Jan 16;48(1):133-146.e6
pubmed: 29287996
Science. 2011 Dec 2;334(6060):1289-93
pubmed: 22033520
Immunity. 2018 May 15;48(5):855-871
pubmed: 29768174
Science. 2014 Dec 12;346(6215):1380-1383
pubmed: 25504724
Nat Med. 2014 Mar;20(3):296-300
pubmed: 24509526
PLoS One. 2010 Jan 20;5(1):e8805
pubmed: 20098712
Nat Commun. 2019 Feb 8;10(1):654
pubmed: 30737386
J Exp Med. 2013 Apr 8;210(4):655-63
pubmed: 23530120
Immunity. 2013 Aug 22;39(2):245-58
pubmed: 23911655
Nat Immunol. 2015 Jun;16(6):571-6
pubmed: 25988889
Science. 2015 Jul 10;349(6244):156-61
pubmed: 26089355
Cell Host Microbe. 2012 Oct 18;12(4):396-407
pubmed: 23084910
Science. 2010 Aug 13;329(5993):811-7
pubmed: 20616231
Nat Med. 2000 Feb;6(2):207-10
pubmed: 10655111
Cell. 2020 Aug 20;182(4):828-842.e16
pubmed: 32645326
J Appl Crystallogr. 2007 Aug 1;40(Pt 4):658-674
pubmed: 19461840
Nature. 2014 May 1;509(7498):55-62
pubmed: 24590074
Nat Commun. 2016 Feb 24;7:10618
pubmed: 26907590
Elife. 2016 Mar 21;5:
pubmed: 26997349
Cell Rep. 2020 Apr 7;31(1):107488
pubmed: 32268107
Science. 2013 May 10;340(6133):751-6
pubmed: 23661761
J Virol. 2014 Mar;88(5):2645-57
pubmed: 24352455
Science. 2010 Aug 13;329(5993):856-61
pubmed: 20616233
Nat Med. 2009 Aug;15(8):951-4
pubmed: 19525965
Nat Med. 1999 Feb;5(2):204-10
pubmed: 9930869
J Exp Med. 2019 Oct 7;216(10):2316-2330
pubmed: 31345931
Immunity. 2019 Jul 16;51(1):141-154.e6
pubmed: 31315032

Auteurs

Emilie Seydoux (E)

Fred Hutchinson Cancer Research Center, Vaccines and Infectious Diseases Division, Seattle, WA 98109, USA.

Yu-Hsin Wan (YH)

Fred Hutchinson Cancer Research Center, Vaccines and Infectious Diseases Division, Seattle, WA 98109, USA.

Junli Feng (J)

Fred Hutchinson Cancer Research Center, Vaccines and Infectious Diseases Division, Seattle, WA 98109, USA.

Abigail Wall (A)

Fred Hutchinson Cancer Research Center, Vaccines and Infectious Diseases Division, Seattle, WA 98109, USA.

Safia Aljedani (S)

Fred Hutchinson Cancer Research Center, Vaccines and Infectious Diseases Division, Seattle, WA 98109, USA.

Leah J Homad (LJ)

Fred Hutchinson Cancer Research Center, Vaccines and Infectious Diseases Division, Seattle, WA 98109, USA.

Anna J MacCamy (AJ)

Fred Hutchinson Cancer Research Center, Vaccines and Infectious Diseases Division, Seattle, WA 98109, USA.

Connor Weidle (C)

Fred Hutchinson Cancer Research Center, Vaccines and Infectious Diseases Division, Seattle, WA 98109, USA.

Matthew D Gray (MD)

Fred Hutchinson Cancer Research Center, Vaccines and Infectious Diseases Division, Seattle, WA 98109, USA.

Lauren Brumage (L)

Fred Hutchinson Cancer Research Center, Vaccines and Infectious Diseases Division, Seattle, WA 98109, USA.

Justin J Taylor (JJ)

Fred Hutchinson Cancer Research Center, Vaccines and Infectious Diseases Division, Seattle, WA 98109, USA; University of Washington, Department of Global Health, Seattle, WA 98195, USA; University of Washington, Department of Immunology, Seattle, WA 98109, USA.

Marie Pancera (M)

Fred Hutchinson Cancer Research Center, Vaccines and Infectious Diseases Division, Seattle, WA 98109, USA.

Leonidas Stamatatos (L)

Fred Hutchinson Cancer Research Center, Vaccines and Infectious Diseases Division, Seattle, WA 98109, USA; University of Washington, Department of Global Health, Seattle, WA 98195, USA. Electronic address: lstamata@fredhutch.org.

Andrew T McGuire (AT)

Fred Hutchinson Cancer Research Center, Vaccines and Infectious Diseases Division, Seattle, WA 98109, USA; University of Washington, Department of Global Health, Seattle, WA 98195, USA. Electronic address: amcguire@fredhutch.org.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH